Acasă › Boala Crohn › Louisiana
Studii clinice pentru Boala Crohn în Louisiana
11 studii pentru Boala Crohn caută participanți în Louisiana.
Orașe în Louisiana
- Lafayette7 studii
- Metairie5 studii
- Shreveport3 studii
- Monroe3 studii
- New Orleans3 studii
- Baton Rouge3 studii
Text oficial al studiului (în engleză)
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Gastro Group and Endocenter: Mandeville, la /ID# 284186, Mandeville
- Metropolitan Gastroenterology Associates - Metairie /ID# 283922, Metairie
- Willis-Knighton Medical Center /ID# 280572, Shreveport
În curs de recrutareFaza 2
Vârste de la 18 la 75 · Toate sexele · Actualizat 2 oct. 2026 · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Baton Rouge General Medical Center - Bluebonnet Campus, Baton Rouge
- Combined Gastro LLC, Lafayette
- GI Alliance, Metairie
În curs de recrutareFaza 4
Vârste de la 18 la 80 · Toate sexele · Actualizat 30 sept. 2026 · NCT06581328A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- Gastroenterology Clinic of Acadiana, Lafayette
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 25 sept. 2026 · NCT07499232A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- Gastroenterology Clinic of Acadiana, Lafayette
- Delta Research Partners, LLC, West Monroe
În curs de recrutareFaza 2/3
Vârste de 18 ani și peste · Toate sexele · Actualizat 25 sept. 2026 · NCT07196722Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Care Access - New Iberia, New Iberia
- Louisiana Research Center, Shreveport
În curs de recrutareFaza 3
Vârste de la 18 la 70 · Toate sexele · Actualizat 24 sept. 2026 · NCT06937099An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- GI Alliance - Baton Rouge-Site Number: 8400129, Baton Rouge
- Tandem Intermediate, LLC - Houma-Site Number: 8400034, Houma
- Texas Digestive Disease Consultants, PLLC d/b/a GI Alliance - Mandeville-Site Number: 8400128, Mandeville
- și încă 4
În curs de recrutareFaza 3
Vârste de la 16 la 80 · Toate sexele · Actualizat 23 sept. 2026 · NCT07184931A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- GI Alliance - Baton Rouge-Site Number: 8400129, Baton Rouge
- Texas Digestive Disease Consultants, PLLC d/b/a GI Alliance - Mandeville-Site Number: 8400128, Mandeville
- GI Alliance - Metairie-Site Number: 8400124, Metairie
- și încă 1
În curs de recrutareFaza 3
Vârste de la 16 la 80 · Toate sexele · Actualizat 23 sept. 2026 · NCT07184944A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
- Tandem Clinical Research, Houma
În curs de recrutareFaza 2
Vârste de la 18 la 85 · Toate sexele · Actualizat 22 sept. 2026 · NCT06226883A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- GI Alliance, Metairie
- Tulane University, New Orleans
În curs de recrutareFaza 4
Vârste de la 18 la 70 · Toate sexele · Actualizat 9 sept. 2026 · NCT06045754A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
- Gastroenterology Clinic of Acadiana, Lafayette
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 28 aug. 2026 · NCT07577843A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Lafayette
- Mirador Therapeutics Selected Site, Marrero
- Mirador Therapeutics Selected Site, Shreveport
În curs de recrutareFaza 2
Vârste de la 18 la 80 · Toate sexele · Actualizat 12 mar. 2026 · NCT07113522Sursă: ClinicalTrials.gov, date preluate la 5 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.